1
|
Blaxall BC, Tschannen-Moran BM, Milano CA
and Koch WJ: Differential gene expression and genomic patient
stratification following left ventricular assist device support. J
Am Coll Cardiol. 41:1096–1106. 2003. View Article : Google Scholar : PubMed/NCBI
|
2
|
Kuwahara K and Nakao K: New molecular
mechanisms for cardiovascular disease: transcriptional pathways and
novel therapeutic targets in heart failure. J Pharmacol Sci.
116:337–342. 2011. View Article : Google Scholar
|
3
|
Proud CG: Ras, PI3-kinase and mTOR
signaling in cardiac hypertrophy. Cardiovasc Res. 63:403–413. 2004.
View Article : Google Scholar : PubMed/NCBI
|
4
|
Duan C, LM, Zhang J and Ma R: RASSF1A: A
potential novel therapeutic target against cardiac hypertrophy.
Prog Biophys Mol Biol. 113:284–288. 2013. View Article : Google Scholar : PubMed/NCBI
|
5
|
Jayakumar P, PK and Sankaran M:
Attenuation of hyperglycemiamediated oxidative stress by
indole-3-carbinol and its metabolite 3,3′-diindolylmethane in
C57BL/6J mice. J Physiol Biochem. 70:525–534. 2014. View Article : Google Scholar : PubMed/NCBI
|
6
|
Kunimasa K, Kobayashi T, Kaji K and Ohta
T: Antiangiogenic effects of indole-3-carbinol and
3,3′-diindolylmethane are associated with their differential
regulation of ERK1/2 and Akt in tube-forming HUVEC. J Nutr.
140:1–6. 2010. View Article : Google Scholar
|
7
|
Azmi AS, AA, Banerjee S, Rangnekar VM,
Mohammad RM and Sarkar FH: Chemoprevention of pancreatic cancer:
Characterization of Par-4 and its modulation by 3,3′
diindolylmethane (DIM). Pahrm Res. 25:2117–2124. 2008. View Article : Google Scholar
|
8
|
Xue L, Firestone GL and Bjeldanes LF: DIM
stimulates IFNgamma gene expression in human breast cancer cells
via the specific activation of JNK and p38 pathways. Oncogene.
24:2343–2353. 2005. View Article : Google Scholar : PubMed/NCBI
|
9
|
Cho HJ, Seon MR, Lee YM, et al:
3,3′-Diindolylmethane suppresses the inflammatory response to
lipopolysaccharide in murine macrophages. J Nutr. 138:17–23.
2008.
|
10
|
Zong J, Deng W, Zhou H, et al:
3,3′-Diindolylmethane protects against cardiac hypertrophy via
5′-adenosine monophosphate-activated protein kinase-α2. PLoS One.
8:e534272013. View Article : Google Scholar
|
11
|
Matsubara H: Renin-angiotensin system in
human failing hearts: message from nonmyocyte cells to myocytes.
Circ Res. 88:861–863. 2001. View Article : Google Scholar : PubMed/NCBI
|
12
|
Weber KT and Brilla CG: Pathological
hypertrophy and cardiac interstitium. Fibrosis and
renin-angiotensin-aldosterone system Circulation. 83:1849–1865.
1991.
|
13
|
Mehta PK and Griendling KK: Angiotensin II
cell signaling: physiological and pathological effects in the
cardiovascular system. Am J Physiol Cell Physiol. 292:C82–C97.
2007. View Article : Google Scholar
|
14
|
Zhou H, Shen DF, Bian ZY, et al:
Activating transcription factor 3 deficiency promotes cardiac
hypertrophy, dysfunction, and fbrosis induced by pressure overload.
PLoS One. 6:e267442011. View Article : Google Scholar
|
15
|
Watkins SJ, Borthwick GM and Arthur HM:
The H9C2 cell line and primary neonatal cardiomyocyte cells show
similar hypertrophic responses in vitro. In vitro Cell Dev Biol
Anim. 47:125–131. 2011. View Article : Google Scholar
|
16
|
Dick E, Rajamohan D, Ronksley J and
Denning C: Evaluating the utility of cardiomyocytes from human
pluripotent stem cells for drug screening. Biochem Soc Trans.
38:1037–1045. 2010. View Article : Google Scholar : PubMed/NCBI
|
17
|
Kimes BW and Brandt BL: Properties of a
clonal muscle cell line from rat heart. Exp Cell Res. 98:367–381.
1976. View Article : Google Scholar : PubMed/NCBI
|
18
|
Zhang P, Hu X, Xu X, et al: AMP activated
protein kinase-alpha2 deficiency exacerbates
pressure-overload-induced left ventricular hypertrophy and
dysfunction in mice. Hyper tension. 52:918–924. 2008. View Article : Google Scholar
|
19
|
Zhou H, Bian ZY, Zong J, et al: Stem cell
antigen 1 protects against cardiac hypertrophy and fibrosis after
pressure overload. Hypertension. 60:802–809. 2012. View Article : Google Scholar : PubMed/NCBI
|
20
|
Heineke J and Molkentin JD: Regulation of
cardiac hypertrophy by intracellular signalling pathways. Nat Rev
Mol Cell Biol. 7:589–600. 2006. View
Article : Google Scholar : PubMed/NCBI
|
21
|
Yan L, Huang H, Tang QZ, et al:
Breviscapine protects against cardiac hypertrophy through blocking
PKC-alpha-dependent signaling. J Cell Biochem. 109:1158–1171.
2010.PubMed/NCBI
|
22
|
Arad M, Seidman CE and Seidman JG:
AMP-activated protein kinase in the heart: role during health and
disease. Circ Res. 100:474–488. 2007. View Article : Google Scholar : PubMed/NCBI
|
23
|
Li HL, Yin R, Chen D, et al: Long-term
activation of adenosine monophosphate-activated protein kinase
attenuates pressure-overload-induced cardiac hypertrophy. J Cell
Biochem. 100:1086–1099. 2007. View Article : Google Scholar : PubMed/NCBI
|
24
|
Garrington TP and Johnson GL: Organization
and regulation of mitogen-activated protein kinase signaling
pathways. Curr Opin Cell Biol. 11:211–218. 1999. View Article : Google Scholar : PubMed/NCBI
|
25
|
Zong J, Zhang DP, Zhou H, et al: Baicalein
protects against cardiac hypertrophy through blocking MEK-ERK1/2
signaling. J Cell Biochem. 2013. View Article : Google Scholar
|